UnitedHealth Group faces a DOJ investigation for possible Medicare fraud, leading to its worst monthly stock slump and raising regulatory and market concerns in the U.S. health insurance sector.

Explore the 2025 anniversaries of foundational U.S. laws: Social Security, Medicare, Medicaid, ADA, and ACA, highlighting their impact on insurance regulation and healthcare policy.

New analysis shows Inflation Reduction Act provisions will reduce Medicare Part D out-of-pocket costs for specialty drugs etanercept, ustekinumab, and ibrutinib, improving affordability for beneficiaries.

Optum is creating AI-driven risk coding to improve Medicare patient assessments, coinciding with DOJ investigations into Medicare Advantage practices by UnitedHealth Group.

The DOJ is investigating UnitedHealth Group for alleged criminal Medicare fraud focused on its Medicare Advantage business, highlighting regulatory and compliance risks for health insurers.

Cutting Medicaid funding shifts costs to Medicare, increasing federal spending and reducing access to care. Learn how Medicaid supports Medicare affordability and prevents costly hospitalizations.

Analysis of inflation rebate implementation under the Inflation Reduction Act highlights the need to include Medicare Advantage enrollees to maximize drug cost savings and deter pharmaceutical price hikes.

Analysis reveals Medicaid funding cuts could worsen health outcomes and increase healthcare costs for low-income and older adults, impacting federal and state budgets.

The U.S. administration advances a 'most favored nation' drug pricing policy to align Medicare prices with global low points, aiming to reduce prescription costs amid industry resistance and anticipated legal challenges.

President Trump's executive order and CMS initiatives mark significant moves to reduce drug prices through broadened Medicare price negotiations including Part B drugs, impacting pharmaceutical industry dynamics and regulatory compliance.